Management of Stage II testicular seminoma over a period of 40 years.
OBJECTIVE
To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy.


METHODS
A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed.


RESULTS
A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19-71). Median follow-up was 21 years (range: 1.2-42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96% for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94%, 72.5%, and 75%, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7%) patients during the follow-up.


CONCLUSIONS
In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma.
Detti
Beatrice
B
Department of Clinical Pathophysiology, Radiotherapy Unit, University of Florence, Florence, Italy. beatrice.detti@googlemail.com
Livi
Lorenzo
L
Scoccianti
Silvia
S
Gacci
Mauro
M
Lapini
Alberto
A
Cai
Tommaso
T
Meattini
Icro
I
Mileo
Anna Maria
AM
Iannalfi
Alberto
A
Bruni
Alessio
A
Biti
Giampaolo
G
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011878:Radiotherapy; D012189:Retrospective Studies; D018239:Seminoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D013736:Testicular Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents